This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Biogen's New Multiple Sclerosis Pill Sales: $192 Million

BIIB Chart BIIB data by YCharts

Updated with new information

CAMBRIDGE, Mass. ( TheStreet) -- Biogen Idec (BIIB - Get Report) reported $192 million in second-quarter sales of its new multiple sclerosis pill Tecfidera and raised earnings guidance for the rest of the year.

Investors had high expectations for Tecfidera going into this morning's earnings report -- looking for end-user sales of at least $90 million in the first three months of the drug's U.S. launch.

Biogen appears to have given investors what they wanted. Total Tecfidera sales to patients -- a true measure of demand for the drug -- were $110 million. The company recorded another $82 million in Tecfidera revenue from wholesaler inventory stocking.

Helped along by the strong Tecfidera launch, Biogen raised guidance for 2013 adjusted earnings to a range of $8.25 to $8.50 per share, above the current consensus of $8.20 per share.

Biogen said it expects to post revenue growth for 2013 in the range of 22 percent to 23 percent, above the 20 percent earnings growth expected by analysts.

Still, Biogen shares were trading flat to slightly down Thursday largely due to high expectations already priced into the stock, plus lingering concerns about the company's ability to launch Tecfidera in Europe on time.

On a conference call, Biogen executives said Tecfidera exclusivity discussions in Europe were taking longer than expected and that any revenue generated by the drug in Europe this year would not be meaningful. Some investors took this to mean that Biogen may not launch the drug in Europe this year, as expected, although the company did not come out and say that specifically.

Back in the U.S., Biogen said the rate at which new multiple sclerosis patients start on Tecfidera may "moderate" in the next quarters because of pent-up demand for the drug at its launch.

For the quarter ended June 30, Biogen reported adjusted net income of $549 million, or $2.30 per share, up 25 percent and 26 percent from the prior year's quarter, respectively.

Revenue in the second quarter totaled $1.7 billion, an 21 percent increase over from the year-ago quarter.

Biogen shares closed Wednesday at $226.61, ahead of the earnings announcement.

-- Reported by Adam Feuerstein in Boston.

Adam Feuerstein writes regularly for TheStreet. In keeping with company editorial policy, he doesn't own or short individual stocks, although he owns stock in TheStreet. He also doesn't invest in hedge funds or other private investment partnerships. Feuerstein appreciates your feedback; click here to send him an email.

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
BIIB $274.99 0.00%
AAPL $93.74 0.00%
FB $117.58 0.00%
GOOG $693.01 0.00%
TSLA $240.76 0.00%


Chart of I:DJI
DOW 17,773.64 -57.12 -0.32%
S&P 500 2,065.30 -10.51 -0.51%
NASDAQ 4,775.3580 -29.9330 -0.62%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs